Eco R1 Capital, LLC Mirati Therapeutics, Inc. Transaction History

Eco R1 Capital, LLC

$2.31 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $69.2 Million - $103 Million	1,648,580 Added 28.68%	7,396,979 $435 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $160 Million - $261 Million	5,748,399 New	5,748,399 $250 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $60.4 Million - $88.1 Million	1,015,572 New	1,015,572 $70.9 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $19.6 Million - $44.4 Million	-500,622 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $38 Million - $75.6 Million	500,622 New	500,622 $41.2 Million
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $61.3 Million - $88.4 Million	-464,298 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $12.1 Million - $17.8 Million	106,449 Added 29.75%	464,298 $77.1 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $20.4 Million - $34 Million	292,849 Added 450.54%	357,849 $27.5 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $1.47 Million - $2.68 Million	20,779 Added 46.99%	65,000 $8.38 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $43.1 Million - $60.7 Million	-553,490 Reduced 92.6%	44,221 $3.45 Million
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $23.9 Million - $42.1 Million	-402,289 Reduced 40.23%	597,711 $61.6 Million
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $15.4 Million - $27.9 Million	352,831 Added 54.52%	1,000,000 $73.3 Million
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $20.7 Million - $30.7 Million	647,169 New	647,169 $27.5 Million
Q1 2018 May 15, 2018	SELL	$17.2 - $34.95 $1.78 Million - $3.61 Million	-103,240 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $1.31 Million - $1.96 Million	103,240	103,240 $1.88 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.

Account